Kazia Presents Paxalisib Research at Breast Cancer Symposium
Kazia Therapeutics has two preclinical paxalisib abstracts accepted for poster presentation at the 2026 San Antonio Breast Cancer Symposium.
Updated on Nov. 2, 2026 in Cancer
Kazia Therapeutics announced that two abstracts on its investigational drug paxalisib were accepted for poster presentation at the 2026 San Antonio Breast Cancer Symposium. The posters will be presented December 8 through 11, 2026, in San Antonio, Texas.
Why it matters
The research explores whether paxalisib, a dual PI3K/mTOR inhibitor, differs biologically from other drugs in its class and whether it can suppress recurrence in breast cancer. Kazia believes the evidence suggests a mechanism beyond conventional kinase inhibition.
The two posters are preclinical studies, with one comparing paxalisib to other dual PI3K/mTOR inhibitors and the other testing it after neoadjuvant chemo-immunotherapy in stage III triple-negative breast cancer. No human clinical outcomes were reported in the announcement, and whether these preclinical findings will translate to patients has not been established.
The players
Kazia Therapeutics Limited
Kazia Therapeutics is an oncology-focused biotechnology company listed on NASDAQ under the ticker KZIA, developing paxalisib for brain tumors and other cancers.
The details
One poster, identified as P4-9-18, examines tumor and immune reprogramming across breast cancer subtypes. A second poster, identified as P4-10-26, studies paxalisib given after standard chemo-immunotherapy in a preclinical triple-negative breast cancer model, examining suppression of local and metastatic recurrence.
Timeline
Dec. 8 through 11, 2026: San Antonio Breast Cancer Symposium poster presentations in San Antonio, Texas.
Big Picture
The posters test whether paxalisib departs from the broader dual PI3K/mTOR inhibitor class, which has been treated as biologically interchangeable. If confirmed, the findings would suggest that drug-level differences within this class matter for breast cancer treatment strategy.
For patients with breast cancer, these findings remain preclinical and do not yet change available treatment options. Any future clinical use would depend on human trial results and regulatory review.
The takeaway
Preclinical research on a drug's mechanism can differ meaningfully from its class-wide assumptions, so patients should look to clinical trial evidence before drawing treatment conclusions. Ongoing human studies will determine whether these laboratory observations matter in practice.
Further reading
Explore more on Cancer research and treatment developments.
Source note: This article includes information reported by Macau Business.
